Xilio Therapeutics (XLO) Common Equity (2020 - 2026)

Xilio Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $72.5 million for Q1 2026.

• Common Equity for Q1 2026 came in at $72.5 million, up 577.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.5 million (up 577.99% YoY), and the FY2025 annual result was $35.3 million, up 100.44% from the prior year.
• Common Equity came in at $72.5 million for Q1 2026 at Xilio Therapeutics, up from $35.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $166.1 million in Q1 2022 to a low of -$8.1 million in Q3 2025.
• The 5-year median for Common Equity is $36.8 million (2023), against an average of $58.8 million.
• Across the five-year window, Common Equity sank 138.6% in 2025 and surged 577.99% in 2026, its largest moves.
• Xilio Therapeutics' Common Equity stood at $105.6 million in 2022, then tumbled by 65.14% to $36.8 million in 2023, then plunged by 52.21% to $17.6 million in 2024, then soared by 100.44% to $35.3 million in 2025, then surged by 105.67% to $72.5 million in 2026.
• The last three Common Equity figures came in at $72.5 million (Q1 2026), $35.3 million (Q4 2025), and -$8.1 million (Q3 2025), per Business Quant data.